And yet, Pfizer's stock price is exactly where it was 5 years ago. Meanwhile Merck & Co (who didn't have a successful COVID vaccine and whose treatment had mediocre results) has seen their stock price double in that same period.
COVID-related things are certainly driving revenue, but I'm not sure they're leading to any kind of long-term profitability.
|